<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1388">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769248</url>
  </required_header>
  <id_info>
    <org_study_id>FNAFNBmucin</org_study_id>
    <nct_id>NCT01769248</nct_id>
  </id_info>
  <brief_title>Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle</brief_title>
  <acronym>MUCIN</acronym>
  <official_title>Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers
      involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine
      needle aspirate - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes.
      This has traditionally been done with fine needle aspirate where a needle is inserted into
      the tumor and potentially malignant cells are extracted for microscopic analysis. More
      recently, a needle that allows a tissue biopsy for histologic analysis has been FDA
      approved.

      The Echotip Procore (Cook Medical) core biopsy needle (ETP), has been demonstrated to
      provide excellent efficacy for core biopsy samples. Final diagnostic yield using this needle
      ranges from 80-90% and appears to be significantly greater than EUS-FNA for lesions
      requiring histology for diagnosis. However, there is currently only limited data from
      prospective studies comparing EUS-FNA to EUS-FNB with the ETP needle. The investigators
      propose a randomized, prospective, cross-over study comparing diagnostic accuracy of EUS-FNA
      to EUS-FNB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers
      involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine
      needle aspirate - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes.
      This has traditionally been done with fine needle aspirate where a needle is inserted into
      the tumor and potentially malignant cells are extracted for microscopic analysis. More
      recently, a needle that allows a tissue biopsy for histologic analysis has been FDA
      approved.

      We will compare tissue samples obtained by standard FNA to FNB with a sample size of 140
      patients with the primary outcome being diagnostic yield. Each patient will be randomized to
      FNA or FNA. If after 3 passes the on-site evaluation remains inadequate, the endoscopist
      will crossover to the other arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Diagnostic Yield of EUS-FNB</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specimen Adequacy as Assessed by Rapid-onsite Evaluation of FNA and FNB</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigators' secondary outcome will assess the ability to obtain an adequate specimen for in room cytologic evaluation as determined by our cytopathologist. This will be defined as a sample that is representative (not necessarily diagnostic) of the lesion in question. This will be expressed as a percentage and compared between FNA and FNB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Whom a Diagnosis is Acheived After Crossover (%)</measure>
    <time_frame>1 yr</time_frame>
    <safety_issue>No</safety_issue>
    <description>As above. Crossover to FNA or FNB occurs after 3 passes without adequate material</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Lymphadenopathy</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fine needle aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fine needle biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fine needle aspiration</intervention_name>
    <description>Fine needle aspiration</description>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <other_name>Echo Tip FNA Needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fine needle biopsy</intervention_name>
    <description>FNB</description>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <other_name>Echo Tip Procore</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 3.1.1 All patients referred for EUS tissue sampling who provide informed consent

        Exclusion Criteria:

          -  3.2.1 Coagulopathy which is not corrected

        3.2.2 Diagnostic EUS determines lesion is not amenable to FNA or FNB
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinadh Komanduri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 11, 2015</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <firstreceived_results_date>March 5, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Sri Komanduri</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>EUS</keyword>
  <keyword>FNA</keyword>
  <keyword>FNB</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fine Needle Aspiration</title>
          <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration using EUS-FNA needles. This was the standard of care arm</description>
        </group>
        <group group_id="P2">
          <title>Fine Needle Biopsy</title>
          <description>Fine needle biopsy
Fine needle biopsy: FNB, test arm for core biopsies, EUS-FNB</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fine Needle Aspiration</title>
          <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration</description>
        </group>
        <group group_id="B2">
          <title>Fine Needle Biopsy</title>
          <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="70"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="107"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.7" spread="14.4"/>
                <measurement group_id="B2" value="64.1" spread="14.4"/>
                <measurement group_id="B3" value="63.8" spread="14.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="66"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="70"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Yield of EUS-FNB</title>
        <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fine Needle Aspiration</title>
            <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration</description>
          </group>
          <group group_id="O2">
            <title>Fine Needle Biopsy</title>
            <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Diagnostic Yield of EUS-FNB</title>
            <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67.1"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specimen Adequacy as Assessed by Rapid-onsite Evaluation of FNA and FNB</title>
        <description>The investigators' secondary outcome will assess the ability to obtain an adequate specimen for in room cytologic evaluation as determined by our cytopathologist. This will be defined as a sample that is representative (not necessarily diagnostic) of the lesion in question. This will be expressed as a percentage and compared between FNA and FNB</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Whom a Diagnosis is Acheived After Crossover (%)</title>
        <description>As above. Crossover to FNA or FNB occurs after 3 passes without adequate material</description>
        <time_frame>1 yr</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>03/2015</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fine Needle Aspiration</title>
          <description>Fine needle aspiration: Fine needle aspiration</description>
        </group>
        <group group_id="E2">
          <title>Fine Needle Biopsy</title>
          <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinadh Komanduri</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-0484</phone>
      <email>koman1973@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
